CLINICAL TRIAL SUMMARY

MDACC Study No:2008-0077 (clinicaltrials.gov NCT No: NCT00611208)
Title:A Phase I/II Study of A-dmDT390-bisFv (UCHT1) Fusion Protein
in Patients with Surface CD3+ Malignant T Cell Diseases
(FDA IND Number: 100712).
Principal Investigator:Madeleine Duvic
Treatment Agent:A-dmDT390-bisFv (UCHT1)
Study Status:Open
Study Description:The goal of this clinical research study is to learn the highest safe dose of
AdmDT390-bisFv (UCHT1) that can be given to patients with a CD3 positive T-cell
cancer.

Hide details for General InformationGeneral Information

Disease Group:Skin
Phase of Study:Phase I/Phase II
Treatment Agents:A-dmDT390-bisFv (UCHT1)
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:5 days (4 day administration cycle)
Supported By:Angiimune
Return Visit:1 return follow-up visit after hospitalization thereafter, the visits are
standard of care
Home Care:n/a


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Madeleine Duvic
Dept:Dermatology
For Clinical Trial Enrollment:713-745-4615
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults